Cytomegalovirus Vertical Transmission Rate According to IgG Avidity Value and Valacyclovir Treatment of Maternal Primary Infection in the First Trimester of Pregnancy
Open Access
- 6 August 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (5) , e417-e423
Abstract
Background: Cytomegalovirus (CMV) serology in the first trimester (T1) of pregnancy relies on immunoglobulin (Ig) G (IgG) and IgM testing, followed by IgG avidity measurement when both IgG and IgM are positive. Valacyclovir is proposed to prevent vertical transmission in maternal primary infection (MPI) during T1. Our objective was to assess the risk of transmission, with and without valacyclovir, based on IgG avidity values and MPI timing. Methods: Cases (2012–2024) with positive or equivocal IgM, intermediate or low IgG avidity (VIDAS and/or LIAISON) in T1, and a CMV PCR performed in amniotic fluid were retrieved from the laboratory software. The MPI date was estimated using a logarithmic model based on VIDAS avidity results. Results: Five hundred and sixty one women (58% untreated, 42% treated) were included. In cases with low avidity and no treatment, transmission was 34% and 31% with VIDAS and LIAISON assays, respectively. Intermediate avidities and no treatment were also associated with high transmission rates (14% and 22%). VIDAS avidity values ≥0.60 or ≥0.50 in samples collected before 12 weeks were associated with 0% and 5% transmission rates, respectively. Without treatment, transmission occurred in 26% (9/34) of women with a LIAISON avidity value between 0.250 and 0.350. Valacyclovir significantly reduced transmission to 2%, 5%, and 16% in preconceptional, periconceptional, and T1 periods, respectively (P = .034, .003, and <.001). Conclusions: Our results suggest that the LIAISON threshold for high avidity should be >0.250. Except for VIDAS avidity values ≥0.60 before 12 weeks, treatment is beneficial for women with positive IgM and low/intermediate avidity, regardless of MPI timing.Keywords
This publication has 18 references indexed in Scilit:
- The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection, following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy. An individual patient data meta-analysisAmerican Journal of Obstetrics and Gynecology, 2023
- New data on efficacy of valacyclovir in secondary prevention of maternal–fetal transmission of cytomegalovirusUltrasound in Obstetrics & Gynecology, 2023
- Human cytomegalovirus non-primary infection during pregnancy: antibody response, risk factors and newborn outcomeClinical Microbiology and Infection, 2022
- Clinical factors associated with cytomegalovirus shedding among seropositive pregnant womenAmerican Journal of Obstetrics & Gynecology MFM, 2022
- Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancyUltrasound in Obstetrics & Gynecology, 2021
- Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequencesAmerican Journal of Obstetrics and Gynecology, 2020
- Cytomegalovirus infection during pregnancy: state of the scienceAmerican Journal of Obstetrics and Gynecology, 2020
- Amniocentesis for prenatal diagnosis of cytomegalovirus infection: challenging the 21 weeks' thresholdPrenatal Diagnosis, 2017
- Clinical evaluation of the Roche Elecsys® CMV IgG Avidity assayEuropean Journal of Clinical Microbiology & Infectious Diseases, 2014
- Re-evaluation of the VIDAS® cytomegalovirus (CMV) IgG avidity assay: Determination of new cut-off values based on the study of kinetics of CMV–IgG maturationJournal of Clinical Virology, 2013